Svetlana Sharoyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Svetlana Sharoyan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alvard Antonyan
Buniatian Institute of Biochemistry, National Academy of Sciences of the Republic of Armenia, Yerevan, Republic of Armenia
3 shared publications A. A. Antonyan
H. Buniatyan Institute of Armenian NAS, Yerevan, Armenia
1 shared publicationA. A. Hovhanesyan
Scientifics and Technical Centre of Organic and Pharmacological Chemistry, A. Mnjoyan Institute of Fine Organic Chemistry of Armenian NAS, Yerevan, Armenia
1 shared publicationA. E. Pogosyan
Scientifics and Technical Centre of Organic and Pharmacological Chemistry, A. Mnjoyan Institute of Fine Organic Chemistry of Armenian NAS, Yerevan, Armenia
1 shared publication- Alexander Nyström
Department of Dermatology, Medical Faculty, Medical Center - University of Freiburg, Freiburg, Germany
1 shared publication - Alexandre Leytens
Department of Biology, University of Fribourg, Fribourg, Switzerland
1 shared publication
Latest Publications
- Open Access
- 1 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2477-2487.e13
Dipeptidyl Peptidase-4–Mediated Fibronectin Processing Evokes a Profibrotic Extracellular Matrix
- 1 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2477-2487.e13
Open AccessDipeptidyl Peptidase-4–Mediated Fibronectin Processing Evokes a Profibrotic Extracellular Matrix
- 29 January 2024
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 35 (4) , 387-398
Diversity of amyloid beta peptide actions
Fibril formation by amyloidogenic proteins and peptides is considered the cause of a number of incurable diseases. One of the most known amyloid diseases is Alzheimer’s disease (AD). Traditionally, amyloidogenic beta peptides Aβ40 and Aβ42 (Aβs) are considered as main causes of AD and the foremost targets in AD fight. The main efforts in pharmacology are aimed at reducing Aβs concentration to prevent their accumulation, aggregation, formation of senile plaques, neuronal death, and neurodegeneration. However, a number of publications have demonstrated certain beneficial physiological effects of Aβs. Simultaneously, it is indicated that the effects of Aβs turn into pathological due to the development of certain diseases in the body. The accumulation of C- and N-terminal truncated Aβs under diverse conditions is supposed to play a role in AD development. The significance of transformation of glutamate residue at positions 3 or 11 of Aβs catalyzed by glutaminyl cyclase making them more degradation resistant, hydrophobic, and prone to aggregation, as well as the participation of dipeptidyl peptidase IV in these transformations are discussed. The experimental data presented confirm the maintenance of physiological, nonaggregated state of Aβs by plant preparations. In conclusion, this review suggests that in the fight against AD, instead of removing Aβs, preference should be given to the treatment of common diseases. Glutaminyl cyclase and dipeptidyl peptidase IV can be considered as targets in AD treatment. Flavonoids and plant preparations that possess antiamyloidogenic propensity are proposed as beneficial neuroprotective, anticancer, and antidiabetic food additives.
- 29 January 2024
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 35 (4) , 387-398
Diversity of amyloid beta peptide actions
Fibril formation by amyloidogenic proteins and peptides is considered the cause of a number of incurable diseases. One of the most known amyloid diseases is Alzheimer’s disease (AD). Traditionally, amyloidogenic beta peptides Aβ40 and Aβ42 (Aβs) are considered as main causes of AD and the foremost targets in AD fight. The main efforts in pharmacology are aimed at reducing Aβs concentration to prevent their accumulation, aggregation, formation of senile plaques, neuronal death, and neurodegeneration. However, a number of publications have demonstrated certain beneficial physiological effects of Aβs. Simultaneously, it is indicated that the effects of Aβs turn into pathological due to the development of certain diseases in the body. The accumulation of C- and N-terminal truncated Aβs under diverse conditions is supposed to play a role in AD development. The significance of transformation of glutamate residue at positions 3 or 11 of Aβs catalyzed by glutaminyl cyclase making them more degradation resistant, hydrophobic, and prone to aggregation, as well as the participation of dipeptidyl peptidase IV in these transformations are discussed. The experimental data presented confirm the maintenance of physiological, nonaggregated state of Aβs by plant preparations. In conclusion, this review suggests that in the fight against AD, instead of removing Aβs, preference should be given to the treatment of common diseases. Glutaminyl cyclase and dipeptidyl peptidase IV can be considered as targets in AD treatment. Flavonoids and plant preparations that possess antiamyloidogenic propensity are proposed as beneficial neuroprotective, anticancer, and antidiabetic food additives.
- 1 December 2023
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 17 (4) , 668-675
Optical Characteristics and Neuroprotective Properties of β-Dimethylaminoethylamide N-Benzoyl-DL-valine Iodmethylate and 1-(β-Diethylaminoethyl)-2-phenyl-4-benzylidene-5-imidazolone
The water and DMSO solutions of two new synthesized compounds, β-dimethylaminoethylamidine N-benzoyl-DL-valineiodomethylate (TVA) and 1-(β-diethylaminoethyl)-2-phenyl-4-benzylidene-5-imidazolone (TVS), were characterized by optical absorbance and fluorescence properties. Earlier, the antiacetylcholinesterase and antibutyrylcholinesterase activities of these compounds have been shown. To prove the eligibility of their use against Alzheimer’s disease, the present study demonstrates the ability of the compounds to reduce the aggregation degree of commercial Aβ(1-42) amyloid peptide in vitro. From the concentration dependences, their IC50 values were estimated in the deceleration of Aβ(1-42) aggregation (1.56 ± 0.3 mM for TVA and 1.8 ± 0.28 mM for TVS). The effective destabilization of the preformed aggregates of the peptide was registered with the IC50 values of 0.54 ± 0.06 and 0.67 ± 0.2 mM, for TVA and TVS, respectively. Cell culture experiments have shown the effectiveness of the synthesized compounds in protection the rat hippocampal cells against cytotoxic action of Aβ(1-42) aggregates: during 7 days incubation, the number of neurospheres per microscopic field in the presence of the peptide aggregates fallen down to 34% of the intact cells, but 2 μg/mL TVA kept the cells on the level of the intact, and 5 μg/mL TVS—on the level of 77% of the intact. Subsequent developments based on these compounds will allow the researchers to create the preparations valid for pre-clinical studies with goal to introduce into medical practice as new remedies in prevention/treatment of Alzheimer’s disease.
- 1 December 2023
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 17 (4) , 668-675
Optical Characteristics and Neuroprotective Properties of β-Dimethylaminoethylamide N-Benzoyl-DL-valine Iodmethylate and 1-(β-Diethylaminoethyl)-2-phenyl-4-benzylidene-5-imidazolone
The water and DMSO solutions of two new synthesized compounds, β-dimethylaminoethylamidine N-benzoyl-DL-valineiodomethylate (TVA) and 1-(β-diethylaminoethyl)-2-phenyl-4-benzylidene-5-imidazolone (TVS), were characterized by optical absorbance and fluorescence properties. Earlier, the antiacetylcholinesterase and antibutyrylcholinesterase activities of these compounds have been shown. To prove the eligibility of their use against Alzheimer’s disease, the present study demonstrates the ability of the compounds to reduce the aggregation degree of commercial Aβ(1-42) amyloid peptide in vitro. From the concentration dependences, their IC50 values were estimated in the deceleration of Aβ(1-42) aggregation (1.56 ± 0.3 mM for TVA and 1.8 ± 0.28 mM for TVS). The effective destabilization of the preformed aggregates of the peptide was registered with the IC50 values of 0.54 ± 0.06 and 0.67 ± 0.2 mM, for TVA and TVS, respectively. Cell culture experiments have shown the effectiveness of the synthesized compounds in protection the rat hippocampal cells against cytotoxic action of Aβ(1-42) aggregates: during 7 days incubation, the number of neurospheres per microscopic field in the presence of the peptide aggregates fallen down to 34% of the intact cells, but 2 μg/mL TVA kept the cells on the level of the intact, and 5 μg/mL TVS—on the level of 77% of the intact. Subsequent developments based on these compounds will allow the researchers to create the preparations valid for pre-clinical studies with goal to introduce into medical practice as new remedies in prevention/treatment of Alzheimer’s disease.
- 1 February 2018
- Published by Elsevier in Neurochemistry International
- Vol. 113, 112-119
Concerted action of dipeptidyl peptidase IV and glutaminyl cyclase results in formation of pyroglutamate-modified amyloid peptides in vitro
- 1 February 2018
- Published by Elsevier in Neurochemistry International
- Vol. 113, 112-119
Concerted action of dipeptidyl peptidase IV and glutaminyl cyclase results in formation of pyroglutamate-modified amyloid peptides in vitro